Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Our innovative AI engine is revolutionizing the drug discovery process, enabling the creation of superior medications at an accelerated pace. The breakthroughs we achieve contribute to the development of medicines more efficiently and effectively. Our portfolio of AI-driven discoveries encompasses entirely owned and collaboratively developed pipeline assets, supported by leading investors in the industry. Atomwise has engineered a cutting-edge machine-learning discovery platform that merges the capabilities of convolutional neural networks with extensive chemical libraries to identify new small-molecule treatments. The key to transforming drug discovery through AI lies in our talented team. We are committed to enhancing our AI platform and leveraging it to revolutionize the discovery of small molecule drugs. It is essential that we confront the most daunting and seemingly insurmountable targets, streamlining the entire drug discovery process to provide developers with increased opportunities for success. Enhanced computational efficiency allows us to screen trillions of compounds virtually, significantly boosting the chances of finding viable solutions. Our impressive model accuracy has successfully addressed the persistent issue of false positives, underscoring the reliability of our approach. Ultimately, our dedication to innovation and excellence sets us apart in the quest for breakthrough therapies.
Description
Streamline the entire selection process for reagents and model systems to eliminate costly inefficiencies and errors that lead to experimental failures. Accelerate project timelines by facilitating the selection of reagents and model systems in a mere 30 seconds, compared to the traditional 12-week duration. This transformation can significantly cut the hard costs associated with consumables, saving organizations millions annually. By restoring valuable research time to scientists, you can enhance the organization’s mission. Experience tangible business benefits from AI through a proven, ready-to-use application. More than 41,200 scientists across 15 of the leading 20 pharmaceutical companies, as well as over 4,450 academic institutions, leverage BenchSci’s AI-Assisted Antibody Selection to design more effective experiments, resulting in documented savings of millions per year in hard costs alone. However, it's important to note that antibodies account for only 40-50% of reagent-related failures. Access a comprehensive array of experimental evidence, along with catalog data for reagents and model systems, all within one user-friendly interface. This platform integrates real-world experiment data sourced from 11.2 million scientific publications, including those published in closed-access journals, providing an unparalleled resource for researchers. With this level of detailed information, scientists can make informed decisions that significantly enhance their research outcomes.
API Access
Has API
No
API Access
Has API
No
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
Yes
Online Support
Yes
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
No
In Person
Yes
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
Yes
In Person
Yes
Vendor Details
Company Name
Atomwise
Founded
2012
Country
United States
Website
www.atomwise.com
Vendor Details
Company Name
BenchSci
Founded
2015
Country
Canada
Website
www.benchsci.com
Product Features
Product Features
Scientific Data Management System (SDMS)
Analytics
No
Artificial Intelligence (AI)
No
Audit
No
Centralized Data Repository
No
Collaboration
No
Compliance
No
Data Security
No
ELN Integration
No
LIMS Integration
No
Workflows
No